Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ikena Oncology, Inc.

1.43
0.0000
Volume:- -
Turnover:- -
Market Cap:69.01M
PE:- -
High:1.43
Open:1.43
Low:1.43
Close:1.43
52wk High:23.28
52wk Low:1.43
Shares:48.26M
Float Shares:33.28M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.0202
ROE:-23.76%
ROA:-18.32%
PB:0.60
PE(LYR):-1.40

Loading ...

Company Profile

Company Name:
Ikena Oncology, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Ikena Oncology, Inc. operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930, a paralog selective inhibitor of the transcriptional enhanced associate domain, a transcription factor in the Hippo signaling pathway. It also develops IK-595, designed to trap MEK and RAF for inhibiting RAS signals than existing inhibitors; and IK-175, a monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors, including urothelial carcinomas. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.